Abstract We examined the effects of angiotensin II (Ang II) and Ang-(l-7) on the release of [ 
H]nor-
A ngiotensin-(l-7) [Ang-(l-7)] is an active compo-/ \ nent of the renin-angiotensin system 1 that lacks JL \~ the phenylalanine present in position 8 of Ang II. It has been shown that although both peptides are products of Ang I metabolism, they result from separate enzymatic pathways. Although angiotensin-converting enzyme promotes Ang II formation, a prolyl endopeptidase converts either Ang I or II into Ang-(l-7).
:w This heptapeptide was found to be present in central and peripheral tissues of rats 4 and dogs 2 and to excite neurons in the central nervous system. 5 ' 6 Although some of the responses elicited by Ang-(l-7) were similar to those of Ang II, 5 -8 different actions for both peptides were also reported; ie, the heptapeptide is not a dipsogen, 9 a constrictor agent of blood vessels, 10 or an aldosterone secretagogue. 10 Moreover, different actions of both peptides in the regulation of cell function were found in isolated rabbit vasa deferentia, where Ang-(1-7) was as potent as Ang II in increasing prostaglandin synthesis but was devoid of the neuromodulatory activity found for Ang II. 11 The aim of the present work was to compare the effects of the heptapeptide and of Ang II in the release of [ 3 H]norepinephrine ([ 3 H]NE) in rat atria isolated with their cardioaccelerans nerves. The effects of both peptides were assayed in the presence of different angiotensin receptor antagonists: DuP 753, which is selective for type 1 angiotensin receptors (AT^; PD 123319, which is selective for type 2 angiotensin receptors (AT 2 ) 1216 ; and saralasin, which blocks both types of angiotensin receptors.
Methods

Synthesis of Ang-(l-7)
The Merrifield solid-phase procedure 17 was employed, using Boc-amino acid derivatives. The crude peptide was purified by high-performance liquid chromatography (HPLC) in a C18 column eluted with a 0% to 40% acetonitrile gradient at a flow rate of 1.8 mL/min. The purified product was characterized as a single component by HPLC and thin-layer chromatography. It showed aspartic acid as the amino-terminal residue as well as the correct amino acid composition and sequence.
Tissue Preparation
Female Wistar rats (180 to 200 g) were anesthetized with ether, and the heart was rapidly removed. Both atria were dissected with their cardioaccelerans nerves in modified Krebs' solution of the following composition (10~3 mol/L): NaCl 118.0, KC1 4.7, CaCl 2 2.6, MgCl 2 1.2, NaHCO 3 25.0, glucose 11.1, EDTA 0.004, and ascorbic acid 0.11. Atropine (1.4x10"' mol/L) was added to the Krebs' solution to exclude any influence of muscarinic receptors on the release of norepinephrine. The atria were set up in a 5-mL isolated organ bath equipped with platinum electrodes for nerve stimulation. Incubations were carried out in the modified Krebs' solution at 37°C with continuous bubbling of 95% O 2 /5% CO 2 .
The spontaneous contractions of the preparation were recorded through a Grass FT03C transducer connected to a Grass polygraph. An equilibration period was allowed to elapse until the basal resting rate did not differ by more than 10 beats per minute during a 10-minute interval.
[ 3 H]NE Overflow Measurement
Endogenous norepinephrine stores were labeled by incubation of the tissue at 37"C for 30 minutes with 5 ^Ci/mL of (±)-7-pH]NE (specific activity, 14.3 Ci/mmol; New England Nuclear Corp) as described by Adler-Graschinsky et al." After incubation, eight consecutive 1-minute washes and then 10 consecutive 5-minute washes with Krebs' solution were performed in every tissue.
Eighty minutes after the end of the incubation of atria with the 3 H transmitter, two consecutive stimulation periods (S, and S 2 ) were applied 30 minutes apart (square-wave pulses 0.5 millisecond long, at 2 Hz and supramaximal voltage, during 2 minutes).
Antagonists and peptides were added 4 and 2 minutes, respectively, before S2 and were replaced every 2 minutes whenever the bath fluid was renewed.
The spontaneous outflow of tritium was measured in 0.5-mL samples collected every 5 minutes. The tritium release induced by nerve stimulation was calculated by subtracting the spontaneous outflow assumed to have occurred in each sample during and after the stimulation period and was expressed as the fractional release per shock (FR): total evoked overflow (nCi) per pulse divided by the total nCi remaining in the tissue at the onset of stimulation. This last value was calculated by addition of the radioactivity lost during the successive washes to that measured in the tissue at the end of the experiment. The spontaneous outflow was the basal resting release obtained in the period immediately before the stimulation.
Statistical Analysis
All values are mean±SEM. Data were submitted to one-way ANOVA. Post hoc analysis with the Schefte test was carried out in every case, and probability values less than .05 were considered significant.
Drugs
Ang II was purchased from Sigma Chemical Co. DuP 753 was obtained from the Du Pont Co. PD 123319 was a gift from Dr Jack Hodges at Parke-Davis.
Results
Effects of Angiotensin Peptides on [ 3 H]N£ Outflow
The spontaneous outflow of [ 3 H]NE 2 minutes before S! expressed as a fraction of the tissue content was 7.0±1.2xl0~3 (n=5) in the control group. This value was not modified in the presence of either 3xlO~8 to 3 x l ( r 7 mol/L Ang-(l-7) or 3xlfr 8 to 3xl0" 7 mol/L Ang II (Fig 1) . On the contrary, the overflow of tritium per shock, which in controls was 15.2±4.8xlO~6 during Si (n=5), was significantly increased by either 3xlO" 8 to 3xlO~7 mol/L Ang II or 3xlO" 8 to 3xl0~7 mol/L Ang-(l-7) (Fig 2) ; ie, the ratio between S 2 and Si, which under control conditions was 0.88 ± 0.02 (n=6), was increased up to 50% by concentrations as low as 3xl0" 
Effects of Angiotensin Receptor Antagonists on the Increase in [ 3 H]NE Release Elicited by Ang II and Ang-(l-7)
As shown in Fig 3, the nonselective antagonist of angiotensin receptors saralasin, at 1 x 10" 7 mol/L, abolished the facilitatory effect on [ When the effects of selective antagonists for AT! and AT 2 receptor subtypes were studied, it was found that the AT, receptor antagonist DuP 753 (lxl(T 6 mol/L) (Fig 4) 7 mol/L Ang II (Fig 5) . The antagonist per se did not modify the [ 
induced release of [
3 H]NE in the presence of Ang-(l-7) was prevented even by a 10 times lower concentration of the AT 2 receptor antagonist (lxlO" 7 mol/L), whereas the effects of Ang II were not prevented by a concentration of this antagonist as high as lxlO~5 mol/L (data not shown).
Discussion
The present study shows that in isolated rat atria Ang II and Ang-(l-7) were equally potent in increasing the [ 3 H]NE release evoked in response to nerve stimulation. The observation that neither peptide modified the basal efflux of [ 3 H]NE probably indicates that they exert their action at a presynaptic site. Moreover, because the effects of the peptides were prevented by different angiotensin receptor antagonists, it appears that this presynaptic site could be an angiotensin receptor.
Despite the fact that Ang II has a high affinity for AT 2 receptors, 16 no AT 2 receptors are involved for this agonist but only for Ang-(l-7). The increase in [
3 H]NE release by nerve stimulation caused by Ang II was selectively prevented by the AT! receptor antagonist DuP 753, suggesting that AT! receptors are involved. Increases in norepinephrine release by nerve stimulation caused by Ang II through the specific interaction with the AT, receptors have been reported in both in vivo and in vitro studies. Among the in vivo effects of Ang II are the results reported by Wong et al 19 and Suzuki et al, 20 who found in anesthetized dogs that the Ang II-induced enhancement of canine renal sympathetic nerve function results from an increase in norepinephrine release through the activation of AT, receptors. Similar results were also obtained in pithed rats under spinal cord stimulation 21 as well as in the paraventricular nucleus of conscious rats submitted to intracerebroventricular injections of pressor doses of Ang II. 22 Among the in vitro assays, a presynaptic modulation by AT, receptors of norepinephrine release elicited by field stimulation was found in superfused slices of rat interscapular fat 23 and in atria isolated from guinea pigs. 24 Despite the fact that, as reported for Ang II, Ang-(1-7) is devoid of dipsogenic, pressor, or direct myotropic effects in rats and humans, 910 the observation that it is as potent as Ang II in increasing the release of norepinephrine caused by nerve stimulation of the rat atria (present results) is coincident with the findings that the heptapeptide is as potent as Ang II in releasing vasopressin from the rat hypothalamo-neurohypophysial system, 7 producing neuronal excitation in rat paraventricular neurons, 5 ' 6 eliciting cardiovascular effects injected into the dorsal medulla of rats, 8 and stimulating prostaglandin release from rabbit vas deferens 11 and Q glioma cells, 25 human astrocytes, 26 and porcine aortic endothelial cells. 27 Nevertheless, our results do not agree with those reported by Trachte et al, 11 who found that the noradrenergic neurogenic contractions of the rabbit vas deferens were potentiated by Ang II but not by the heptapeptide.
The facilitatory action on the sympathetic neurotransmission elicited in the rat atria by both Ang II and Ang-(l-7) appears to be mediated by stimulation of AT, receptors. Moreover, the effect of Ang-(l-7) seems to additionally involve the activation of AT 2 receptors. Identical biological activity caused by both peptides but coupled to the activation of different angiotensin receptor subtypes has also been reported by Jaiswal et al 28 for the increase of prostaglandin synthesis caused by the peptides in cultured human astrocytes, which was mediated through both ATj and AT 2 receptors in the case of Ang II and solely through AT 2 receptors in the case of Ang-(l-7). Hence, it appears that tissue and species differences could be critical in determining either similarities or differences between the actions of both peptides.
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